What is DAMORA THERAPEUT's earnings per share (EPS)?

DAMORA THERAPEUT (DMRA) reported diluted earnings per share of $3.98 for fiscal year 2025. This represents a 121.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

DAMORA THERAPEUT Financials

DMRA

FY2025 annual

Revenue Not reported for FY2025

Net Income -$209.8M -878.8% YoY

EPS (Diluted) $3.98 +121.5% YoY

Free Cash Flow Not reported for FY2025

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows DAMORA THERAPEUT (DMRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI DMRA FY2025 2026-05-12

Damora’s current business mechanic is financed research, where capital raises now shape liquidity far more than operations do.

In FY2025, net loss reached -$209.8M while operating cash burn was only -$6.7M, a mismatch that usually means the earnings hit came largely from non-cash accounting effects rather than cash leaving the business at the same rate. Because financing added $266.8M, cash finished at $257.6M, so the balance sheet became stronger even as reported earnings looked dramatically worse.

Spending mix turned back toward R&D: research expense climbed to $26.9M in FY2025 after dropping to $6.4M in FY2024. SG&A kept easing lower, which suggests the company restarted program activity without rebuilding corporate overhead at the same pace.

With $257.6M of cash and only $20.1M of total liabilities, Damora has a balance sheet funded mainly by equity capital rather than creditors or internal cash generation. Nearly all assets are liquid, so the balance sheet currently acts more like a research war chest than a fixed operating asset base.

Financial Health Signals

Financial health score pending refresh

We are recalculating DAMORA THERAPEUT's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

DAMORA THERAPEUT passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

DAMORA THERAPEUT reported a net loss of $209.8M while operations used $6.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

DAMORA THERAPEUT reported an operating loss of $210.9M against $1.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$210.8M

YoY-848.1%

DAMORA THERAPEUT's EBITDA was -$210.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 848.1% from the prior year.

Net Income

-$209.8M

YoY-878.8%

DAMORA THERAPEUT reported -$209.8M in net income in fiscal year 2025. This represents a decrease of 878.8% from the prior year.

EPS (Diluted)

$3.98

YoY+121.5%

DAMORA THERAPEUT earned $3.98 per diluted share (EPS) in fiscal year 2025. This represents an increase of 121.5% from the prior year.

Revenue

Not reported for fiscal year 2025.

Cash & Balance Sheet

Cash & Debt

$257.6M

YoY+1717.5%

5Y CAGR+9.5%

DAMORA THERAPEUT held $257.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Dividends Per Share

$0.00

DAMORA THERAPEUT paid $0.00 per share in dividends in fiscal year 2025.

Shares Outstanding

YoY+21.3%

DAMORA THERAPEUT had 2M shares outstanding in fiscal year 2025. This represents an increase of 21.3% from the prior year.

Free Cash Flow

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

-87.3%

YoY+48.1pp

5Y CAGR-66.2pp

DAMORA THERAPEUT's ROE was -87.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 48.1 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$26.9M

YoY+320.1%

5Y CAGR+1.8%

DAMORA THERAPEUT invested $26.9M in research and development in fiscal year 2025. This represents an increase of 320.1% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

Capital Expenditures

Not reported for fiscal year 2025.

DMRA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

DMRA annual income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19
R&D Expenses	N/A	$26.9M+320.1%	$6.4M-73.1%	$23.8M-50.7%	$48.2M+25.2%	$38.5M+56.3%	$24.6M+24.8%	$19.7M
SG&A Expenses	N/A	$9.7M-7.8%	$10.5M-17.2%	$12.7M-2.4%	$13.0M-5.4%	$13.7M+52.5%	$9.0M+268.5%	$2.4M
Operating Income	N/A	-$210.9M-847.3%	-$22.3M+44.2%	-$39.9M+34.8%	-$61.2M-17.2%	-$52.2M-55.3%	-$33.6M-186.3%	$39.0M
Interest Expense	N/A	$1.2M+38.3%	$844K-50.0%	$1.7M+133.9%	$722K+362.8%	$156K	N/A	N/A
Income Tax	N/A	$50K+22.0%	$41K	$0	$0	$0	$0	$0
Net Income	N/A	-$209.8M-878.8%	-$21.4M+44.1%	-$38.3M+37.8%	-$61.6M-19.1%	-$51.8M-48.6%	-$34.8M+4.6%	-$36.5M
EPS (Diluted)	—	$3.98+121.5%	-$18.53+48.6%	-$36.08	-$2.43-18.5%	-$2.05	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
R&D Expenses	$23.8M	N/A	$1.4M-3.3%	$1.5M+116.1%	$678K	N/A	$1.1M-40.4%	$1.8M
SG&A Expenses	$7.0M	N/A	$1.7M-11.0%	$2.0M+1.8%	$1.9M	N/A	$2.7M-1.0%	$2.8M
Operating Income	-$30.8M	N/A	-$3.2M+7.7%	-$3.4M-31.6%	-$2.6M	N/A	-$3.8M+31.1%	-$5.6M
Interest Expense	$3.1M	N/A	$42K-16.0%	$50K-32.4%	$74K	N/A	$146K-31.5%	$213K
Income Tax	$42K	N/A	$0-100.0%	$4K+100.0%	$2K	N/A	$7K-83.3%	$42K
Net Income	-$27.8M	N/A	-$3.1M+8.8%	-$3.4M-35.7%	-$2.5M	N/A	-$3.9M+27.3%	-$5.3M
EPS (Diluted)	-$0.62	N/A	-$2.36+9.2%	-$2.60-35.4%	-$1.92	N/A	-$3.39	-$4.92

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.

TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

DMRA Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

DMRA annual balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$260.5M+1420.7%	$17.1M-55.2%	$38.2M-47.8%	$73.2M-40.1%	$122.2M-28.8%	$171.6M+203.1%	$56.6M
Current Assets	$260.4M+1446.5%	$16.8M-54.2%	$36.8M-42.5%	$63.9M-42.0%	$110.1M-35.0%	$169.3M+201.9%	$56.1M
Cash & Equivalents	$257.6M+1717.5%	$14.2M-34.0%	$21.5M-34.5%	$32.8M-47.6%	$62.6M-61.8%	$163.6M+1348.4%	$11.3M
Total Liabilities	$20.1M+1448.6%	$1.3M-77.9%	$5.9M-48.4%	$11.4M+129.1%	$5.0M-18.3%	$6.1M-95.2%	$127.8M
Current Liabilities	$20.1M+1576.4%	$1.2M-79.5%	$5.8M-47.5%	$11.1M+144.4%	$4.5M-18.4%	$5.6M-29.8%	$7.9M
Total Equity	$240.4M+1418.4%	$15.8M-51.0%	$32.3M-47.6%	$61.8M-47.3%	$117.2M-29.2%	$165.5M+332.6%	-$71.1M
Retained Earnings	-$487.4M-75.6%	-$277.5M-8.4%	-$256.1M-17.6%	-$217.7M-39.5%	-$156.1M-49.6%	-$104.4M-50.1%	-$69.5M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$535.4M+105.5%	$260.5M+2326.7%	$10.7M-21.6%	$13.7M-10.9%	$15.4M-10.3%	$17.1M-26.7%	$23.4M-14.4%	$27.3M
Current Assets	$535.4M+105.6%	$260.4M+2561.2%	$9.8M-24.9%	$13.0M-12.7%	$14.9M-11.4%	$16.8M-20.5%	$21.2M-15.9%	$25.2M
Cash & Equivalents	$532.9M+106.9%	$257.6M+3287.1%	$7.6M-25.5%	$10.2M-14.5%	$11.9M-15.8%	$14.2M-28.0%	$19.7M-13.9%	$22.9M
Total Liabilities	$23.8M+18.3%	$20.1M+638.3%	$2.7M-0.3%	$2.7M+65.3%	$1.7M+27.3%	$1.3M-46.7%	$2.4M-34.2%	$3.7M
Current Liabilities	$23.8M+18.7%	$20.1M+665.0%	$2.6M-0.2%	$2.6M+69.5%	$1.6M+29.6%	$1.2M-51.0%	$2.4M-34.2%	$3.7M
Total Equity	$511.6M+112.8%	$240.4M+2902.1%	$8.0M-26.9%	$11.0M-20.1%	$13.7M-13.4%	$15.8M-24.4%	$20.9M-11.2%	$23.6M
Retained Earnings	-$515.1M-5.7%	-$487.4M-70.0%	-$286.6M-1.1%	-$283.5M-1.2%	-$280.1M-0.9%	-$277.5M-2.5%	-$270.8M-1.5%	-$266.9M

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

DMRA Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

DMRA annual cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$24.9M	-$6.7M+63.9%	-$18.6M+49.5%	-$36.9M+14.0%	-$42.9M+17.9%	-$52.3M-36.9%	-$38.2M-97.7%	-$19.3M
Capital Expenditures	N/A	N/A	N/A	N/A	$196K-12.1%	$223K	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	-$43.1M+17.9%	-$52.5M	N/A	N/A
Investing Cash Flow	N/A	-$17.4M-249.1%	$11.7M-47.8%	$22.3M+80.3%	$12.4M+125.8%	-$48.0M	N/A	-$326K
Financing Cash Flow	N/A	$266.8M	N/A	$2.9M+467.3%	$507K	N/A	$187.4M	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$20.6M-3739.2%	$566K+121.6%	-$2.6M-16.9%	-$2.2M+8.3%	-$2.4M+50.6%	-$4.9M-35.2%	-$3.7M+11.0%	-$4.1M
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$6.0M
Financing Cash Flow	$295.9M	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

DMRA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

DMRA annual financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19
Return on Equity	-87.3%+48.1pp	-135.4%-16.8pp	-118.6%-18.8pp	-99.8%-55.6pp	-44.1%-23.1pp	-21.1%	N/A
Return on Assets	-80.5%+44.6pp	-125.1%-24.8pp	-100.3%-16.1pp	-84.2%-41.9pp	-42.4%-22.0pp	-20.3%+44.2pp	-64.5%
Current Ratio	12.98-1.1x	14.07+7.8x	6.31+0.6x	5.75-18.5x	24.23-6.2x	30.42+23.3x	7.07
Debt-to-Equity	0.080.0x	0.08-0.1x	0.180.0x	0.19+0.1x	0.040.0x	0.04	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Return on Equity	-5.4%	N/A	-39.1%-7.7pp	-31.4%-12.9pp	-18.5%	N/A	-18.6%+4.1pp	-22.6%
Return on Assets	-5.2%	N/A	-29.2%-4.1pp	-25.1%-8.6pp	-16.5%	N/A	-16.6%+2.9pp	-19.6%
Current Ratio	22.48+9.5x	12.98+9.2x	3.73-1.2x	4.96-4.7x	9.62-4.4x	14.07+5.4x	8.68+1.9x	6.79
Debt-to-Equity	0.050.0x	0.08-0.3x	0.34+0.1x	0.25+0.1x	0.120.0x	0.080.0x	0.120.0x	0.16

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Where DAMORA THERAPEUT Ranks

Frequently Asked Questions

Is DAMORA THERAPEUT profitable?

No, DAMORA THERAPEUT (DMRA) reported a net income of -$209.8M in fiscal year 2025.

What is DAMORA THERAPEUT's EBITDA?

DAMORA THERAPEUT (DMRA) had EBITDA of -$210.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is DAMORA THERAPEUT's return on equity (ROE)?

DAMORA THERAPEUT (DMRA) has a return on equity of -87.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is DAMORA THERAPEUT's operating cash flow?

DAMORA THERAPEUT (DMRA) recorded an outflow of $6.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are DAMORA THERAPEUT's total assets?

DAMORA THERAPEUT (DMRA) had $260.5M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does DAMORA THERAPEUT spend on research and development?

DAMORA THERAPEUT (DMRA) invested $26.9M in research and development during fiscal year 2025.

How many shares does DAMORA THERAPEUT have outstanding?

DAMORA THERAPEUT (DMRA) had 2M shares outstanding as of fiscal year 2025.

What is DAMORA THERAPEUT's current ratio?

DAMORA THERAPEUT (DMRA) had a current ratio of 12.98 as of fiscal year 2025, which is generally considered healthy.

What is DAMORA THERAPEUT's debt-to-equity ratio?

DAMORA THERAPEUT (DMRA) had a debt-to-equity ratio of 0.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is DAMORA THERAPEUT's return on assets (ROA)?

DAMORA THERAPEUT (DMRA) had a return on assets of -80.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is DAMORA THERAPEUT's cash runway?

Based on fiscal year 2025 data, DAMORA THERAPEUT (DMRA) had $257.6M in cash against an annual operating cash burn of $6.7M. This gives an estimated cash runway of approximately 460 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is DAMORA THERAPEUT's Piotroski F-Score?

DAMORA THERAPEUT (DMRA) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are DAMORA THERAPEUT's earnings high quality?

DAMORA THERAPEUT (DMRA) reported a net loss of $209.8M while operations used $6.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can DAMORA THERAPEUT cover its interest payments?

DAMORA THERAPEUT (DMRA) reported an operating loss of $210.9M against $1.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.